Lipoprotein(a) in Modern Atherosclerosis Medicine: From Underrecognized Risk to a New Diagnostic and Therapeutic Paradigm

Mykola Iabluchanskyi and Pavlo Garkaviy

Abstract

Lipoprotein(a) [Lp(a)] has moved from the periphery of cardiovascular medicine to a position of growing clinical and conceptual importance. It is now recognized as a causal, largely genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis, while broader testing recommendations and emerging targeted therapies are reshaping its practical relevance. Yet the significance of Lp(a) may extend beyond its role as an additional inherited biomarker. This commentary argues that Lp(a) should be reconsidered as a marker and mediator of a distinct disorder of lipid homeostasis, one that links atherogenesis, vascular inflammation, thrombogenicity, and calcific remodeling into a recognizable vascular phenotype. From this perspective, the clinical importance of Lp(a) lies not only in its capacity to refine cardiovascular risk, but in its potential to reorganize diagnostic reasoning and therapeutic strategy. Elevated Lp(a) may identify patients in whom conventional lipid measures underestimate inherited vascular vulnerability, residual risk, or disease mechanisms not fully captured by LDL-C–centered models. The arrival of potent RNA-targeted therapies further strengthens the need for such a conceptual shift, because direct pharmacological lowering of Lp(a) may soon transform a previously frustrating measurement into a pathway-specific therapeutic target. If this interpretation is correct, Lp(a) should no longer be treated as an auxiliary laboratory parameter, but as a distinct diagnostic and therapeutic axis within modern atherosclerosis medicine.

Introduction

For many years, lipoprotein(a) [Lp(a)] remained in an uncertain position within cardiovascular medicine: important enough to attract scientific attention, yet insufficiently integrated into routine clinical logic. This situation has changed substantially. Lp(a) is now supported by mechanistic, epidemiological, and genetic evidence as a causal contributor to atherosclerotic cardiovascular disease and calcific aortic valve stenosis, and contemporary statements increasingly support at least once-in-a-lifetime measurement in adults. In parallel, several targeted therapies directed at apo(a) synthesis or Lp(a) assembly are moving through clinical development, giving Lp(a) renewed clinical relevance.

Yet the field may still be underinterpreting what elevated Lp(a) means biologically. The dominant view treats Lp(a) as an inherited risk factor layered onto standard dyslipidemia. That view is correct, but incomplete. A more informative interpretation is that Lp(a) may identify a distinct disturbance of lipid homeostasis—a specific mode of vascular lipid handling in which atherogenic transport, inflammatory signaling, thrombogenic potential, and calcific transformation are unusually tightly linked. This commentary develops that argument and proposes that Lp(a) should be understood not merely as an additional biomarker, but as a distinct diagnostic and therapeutic axis in modern atherosclerosis medicine.

Historical neglect

The underuse of Lp(a) in clinical medicine was not due to irrelevance, but to a convergence of practical and conceptual barriers. Lp(a) is largely genetically determined, exhibits marked interindividual variability, and is minimally influenced by lifestyle, making it less attractive in an era that prioritized modifiable lipid parameters. Assay standardization was also problematic, with persistent confusion arising from size heterogeneity of apo(a), variability in reporting units, and the absence of a robust conversion factor between mg/dL and nmol/L.

Conceptually, Lp(a) remained overshadowed by the success of LDL-C–centered lipidology. Because LDL-C lowering was highly effective and clinically actionable, other apoB-containing particles were often interpreted mainly in relation to LDL-C rather than on their own biological terms. In this framework, Lp(a) was usually treated as a risk-enhancing modifier rather than as a distinct pathogenic entity. The absence of dedicated therapies reinforced that marginalization. However, once causal evidence, broader testing recommendations, and potent targeted therapies converge, continued underestimation of Lp(a) is no longer simply conservative practice; it becomes a failure of disease recognition.

Biological distinctiveness

Lp(a) is structurally and functionally different from conventional LDL particles. It is an LDL-like particle containing apoB100 covalently linked to apolipoprotein(a) [apo(a)], a highly polymorphic protein derived evolutionarily from plasminogen. This structure gives Lp(a) a dual biological identity: it remains an apoB-containing lipoprotein capable of participating in arterial lipid deposition, yet it also acquires properties related to thrombosis, impaired fibrinolysis, inflammatory signaling, and calcific activity.

Current evidence indicates that Lp(a) carries oxidized phospholipids, preferentially accumulates within the vessel wall, promotes endothelial activation and monocyte recruitment, and is implicated in the progression of calcific aortic valve disease. Its clinical associations therefore extend beyond coronary atherosclerosis to ischemic stroke, peripheral artery disease, recurrent cardiovascular events, and aortic valve stenosis. These features suggest that Lp(a) is not simply another cholesterol-associated variable. It occupies a biological intersection where lipid transport, inflammation, thrombosis, and calcification converge.

Lp(a) and lipid homeostasis

A more original and clinically productive interpretation is to understand elevated Lp(a) as a sign of a distinct disorder of lipid homeostasis. The usual formulation—“Lp(a) is genetically determined and increases cardiovascular risk”—describes inheritance and prognosis, but not the full pathophysiological logic of the particle. High Lp(a) may indicate not merely greater exposure to an atherogenic particle, but exposure to a form of lipid transport that endogenous compensatory systems do not adequately neutralize.

In that sense, Lp(a) may identify a specific atherogenic program rather than only a quantitative abnormality. The issue is not simply the mass of cholesterol being carried, but the biological form in which it is carried and the vascular response that this form preferentially elicits. Because Lp(a) combines apoB-driven lipid delivery with apo(a)-associated inflammatory, antifibrinolytic, and procalcific properties, it may create a metabolically distinct vascular burden. This helps explain why Lp(a) is linked not only to plaque formation, but also to recurrent events, inflammatory plaque vulnerability, and calcific valve disease.

Under this view, Lp(a) is more than an “extra” risk factor beside LDL-C. It is a marker and mediator of a particular failure mode of lipid homeostasis—one in which lipid burden is trafficked in a biologically disadvantageous form that favors persistent arterial retention, thromboinflammatory amplification, and calcific remodeling. This interpretation moves the field from descriptive association toward biological classification.

Diagnostic consequences

If elevated Lp(a) identifies a distinct homeostatic and vascular phenotype, then diagnostic practice must change accordingly. Recent recommendations increasingly support broad one-time measurement in adults, and some statements advise repeat testing in selected borderline or clinically evolving situations. However, the clinical meaning of testing should go beyond simple documentation.

A high Lp(a) level should trigger a different interpretive framework. It may explain premature atherosclerotic disease, recurrent events despite apparently satisfactory LDL-C control, vascular disease disproportionate to standard risk estimates, or the presence of calcific aortic valve pathology. It should also strengthen the case for cascade testing in relatives, because Lp(a)-related risk is largely inherited and can identify silent familial vulnerability before clinical events occur.

This diagnostic shift is important because routine lipid panels often underestimate the biology of risk in high-Lp(a) patients. In such individuals, standard LDL-C–based reasoning may identify risk incompletely, whereas an Lp(a)-aware approach better captures the inherited architecture of disease. Diagnosis should therefore move from merely noting elevated Lp(a) to identifying an Lp(a)-associated vascular phenotype.

Risk reclassification

The incorporation of Lp(a) into clinical decision-making changes more than laboratory interpretation; it changes risk classification itself. Elevated Lp(a) may account for substantial residual risk at any level of LDL-C or apoB and may identify patients whose vascular phenotype is more severe than their conventional risk profile would suggest. In this sense, Lp(a) does not simply enhance risk estimation; it can alter the biological meaning of risk.

This is especially relevant in primary prevention, where markedly elevated Lp(a) may justify earlier and more intensive intervention despite only modest abnormalities in standard lipid measurements. In secondary prevention, high Lp(a) may clarify why recurrent events occur despite aggressive LDL-C lowering and otherwise guideline-directed therapy. Once identified, Lp(a) should therefore influence not only prognosis, but the threshold for preventive action.

Therapeutic transition

Historically, the major limitation of Lp(a) testing was therapeutic inertia. Elevated levels could be identified, but specific options were limited. Conventional lipid-lowering therapies have not provided pathway-specific control of Lp(a). Statins may slightly increase Lp(a) levels, whereas PCSK9 inhibitors reduce Lp(a) modestly—typically by about 20%—although they are not prescribed specifically for this purpose because Lp(a) lowering is not a formal labeled indication. Lipoprotein apheresis remained the most effective established intervention, but its use was limited to selected high-risk settings.

This is now changing. Antisense oligonucleotides, small interfering RNAs, and small-molecule approaches targeting apo(a) synthesis or Lp(a) assembly have demonstrated profound reductions in circulating Lp(a), and phase 3 outcome trials are underway to determine whether this translates into fewer cardiovascular events. Once a previously neglected biomarker becomes directly targetable, its meaning changes. Lp(a) is no longer only a risk sign; it becomes a pathway-specific therapeutic target.

That shift has major implications. If Lp(a) reflects a distinct metabolic and vascular phenotype, then lowering it is not merely numerical correction. It is a form of pathway interruption. This may eventually require more differentiated treatment logic in which some patients are classified primarily by LDL-C–driven disease, others by a broader burden of apoB-containing lipoproteins, and others by an Lp(a)-associated pattern of inherited, thromboinflammatory, and calcific atherogenesis.

A new paradigm

These developments support a broader conclusion: Lp(a) should be repositioned as a separate dimension within modern atherosclerosis medicine. Its importance lies not only in its independent risk association, but in its ability to reveal a particular biology of vascular disease—one that combines inherited susceptibility, atypical lipid handling, inflammatory activation, thrombogenicity, and calcific transformation.

This is the central conceptual claim of the present article. The novelty does not lie in reasserting that Lp(a) matters; that is already well supported. The novelty lies in treating elevated Lp(a) as the signature of a specific lipid-handling and vascular response pattern, and in arguing that this reinterpretation should reshape how atherosclerosis is diagnosed, stratified, and treated.

Conclusion

Lp(a) has moved beyond the status of an underrecognized inherited risk factor. It now stands at the intersection of causal cardiovascular biology, emerging targeted therapy, and a changing diagnostic landscape. The most important next step is broader testing accompanied by a shift in interpretation: elevated Lp(a) should be read as a sign of a distinct vascular and metabolic phenotype rather than as an auxiliary laboratory abnormality.

If this view is correct, then the future of Lp(a) medicine lies in a new clinical logic. That logic begins with detection, extends to family-based and phenotype-based risk classification, and culminates in pathway-specific therapy. In that sense, Lp(a) is not merely becoming more visible within atherosclerosis medicine; it is helping redefine it. 

Selected literature

Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48–e60.

Silbernagel G, Chapman MJ, Catapano AL, et al. Lipoprotein(a) as a pharmacological target: Premises, promises, and prospects. Circulation. 2025;151(6):400–415.

Björnson E, Adiels M, Taskinen MR, Burgess S, Chapman MJ, Packard CJ, Borén J. Lipoprotein(a) is markedly more atherogenic than LDL: An apolipoprotein B-based genetic analysis. J Am Coll Cardiol. 2024;83(3):385–395.

Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: New insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465–474.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239–2253.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense inhibition of apolipoprotein(a) to lower plasma lipoprotein(a) levels in humans. Lancet. 2015;386(10002):1472–1483.

Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503–512.

Kaiser Y, van der Toorn JE, Damman P, et al. Lipoprotein(a) and calcific aortic valve disease: A systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:877140.